Skip to main content
NCBI home page
The Indian Journal of Surgery logoLink to The Indian Journal of Surgery
. 2010 Jan 13;71(6):299–307. doi: 10.1007/s12262-009-0084-6

Controversies and challenges in the management of well-differentiated thyroid cancer

N Gopalakrishna Iyer 1, Ashok R Shaha 1,✉
PMCID: PMC3452739  PMID: 23133181

Abstract

The incidence of well-differentiated thyroid cancer has seen a worldwide increase in the last three decades, although whether this is due to a ‘true increase’ in incidence or simply increased detection of otherwise subclinical disease remains undetermined. Nonetheless, this rising incidence has fuelled an interest in early diagnosis, treatment and follow-up of thyroid cancer along with greater public awareness. The treatment of thyroid cancer revolves around appropriate surgical intervention, minimising complications and the use of adjuvant therapy in select circumstances. Prognostic features and risk stratification are crucial in determining the appropriate treatment. There continues to be considerable debate in several aspects of management in these patients, and there is limited prospective data to direct therapy, hence limiting decision-making to retrospective analyses, treatment guidelines based on expert opinion and personal philosophies. The major controversies are related to diagnostic work-up, extent of surgery and postoperative management including the role of radioactive iodine. There are also differences in opinion regarding management of nodal metastases and follow-up protocols. As overall survival in well-differentiated thyroid cancer exceeds 95%, it is important to reduce over-treating the large majority of patients, and focus limited resources on high-risk patients who require aggressive treatment and closer attention. There needs to be a concerted effort on the part of a multidisciplinary team to recognise the nuances in treating well-differentiated thyroid cancer.

Keywords: Thyroid, Surgery, Imaging, Controver

Full Text

The Full Text of this article is available as a PDF (220.7 KB).

References

  • 1.Santos Silva I., Swerdlow A.J. Thyroid cancer epidemiology in England and Wales: Time trends and geographical distribution. Br J Cancer. 1993;67(2):330–340. doi: 10.1038/bjc.1993.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pettersson B., Adami H.O., Wilander E., Coleman M.P. Trends in thyroid cancer incidence in Sweden, 1958–1981, by histopathologic type. Int J Cancer. 1991;48(1):28–33. doi: 10.1002/ijc.2910480106. [DOI] [PubMed] [Google Scholar]
  • 3.Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–2167. doi: 10.1001/jama.295.18.2164. [DOI] [PubMed] [Google Scholar]
  • 4.Randolph G.W., Thompson G.B., Branovan D.I., Tuttle R.M. Treatment of thyroid cancer: A basic review. Int J Radiat Oncol Biol Phys. 2007;69(2Suppl):S92–97. doi: 10.1016/j.ijrobp.2007.06.027. [DOI] [PubMed] [Google Scholar]
  • 5.Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns] Cancer. 1998;83(12):2638–2648. doi: 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  • 6.Bilimoria K.Y., Bentrem D.J., Ko C.Y., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–381. doi: 10.1097/SLA.0b013e31814697d9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Atli M., Akgul M., Saryal M., Daglar G., Yasti A.C., Kama N.A. Thyroid incidentalomas: Prediction of malignancy and management. Int Surg. 2006;91(4):237–244. [PubMed] [Google Scholar]
  • 8.Gough J., Scott-Coombes D., Fausto Palazzo F. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg. 2008;32(7):1264–1268. doi: 10.1007/s00268-008-9503-2. [DOI] [PubMed] [Google Scholar]
  • 9.Howlett D.C., Speirs A. The thyroid incidentaloma-ignore or investigate? J Ultrasound Med. 2007;26(10):1367–1371. doi: 10.7863/jum.2007.26.10.1367. [DOI] [PubMed] [Google Scholar]
  • 10.Frates M.C., Benson C.B., Charboneau J.W., et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q. 2006;22(4):231–238. doi: 10.1097/01.ruq.0000226877.19937.a1. [DOI] [PubMed] [Google Scholar]
  • 11.Kim E.K., Park C.S., Chung W.Y., et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178(3):687–691. doi: 10.2214/ajr.178.3.1780687. [DOI] [PubMed] [Google Scholar]
  • 12.Katz S.C., Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg. 2008;207(2):259–264. doi: 10.1016/j.jamcollsurg.2008.02.013. [DOI] [PubMed] [Google Scholar]
  • 13.Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505. doi: 10.1210/jc.2005-1534. [DOI] [PubMed] [Google Scholar]
  • 14.Are C., Hsu J.F., Ghossein R.A., Schoder H., Shah J.P., Shaha A.R. Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol. 2007;14(11):3210–3215. doi: 10.1245/s10434-007-9531-4. [DOI] [PubMed] [Google Scholar]
  • 15.Papini E., Guglielmi R., Bianchini A., et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87(5):1941–1946. doi: 10.1210/jc.87.5.1941. [DOI] [PubMed] [Google Scholar]
  • 16.Shaha A.R. Controversies in the management of thyroid nodule. Laryngoscope. 2000;110(2Pt1):183–193. doi: 10.1097/00005537-200002010-00001. [DOI] [PubMed] [Google Scholar]
  • 17.Shaha A.R. Advances in the management of thyroid cancer. Int J Surg. 2005;3(3):213–220. doi: 10.1016/j.ijsu.2005.03.012. [DOI] [PubMed] [Google Scholar]
  • 18.Leenhardt L., Hejblum G., Franc B., et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab. 1999;84(1):24–28. doi: 10.1210/jc.84.1.24. [DOI] [PubMed] [Google Scholar]
  • 19.Shah J.P., Loree T.R., Dharker D., Strong E.W. Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg. 1993;166(4):331–335. doi: 10.1016/S0002-9610(05)80326-5. [DOI] [PubMed] [Google Scholar]
  • 20.Shah J.P., Loree T.R., Dharker D., Strong E.W., Begg C., Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164(6):658–661. doi: 10.1016/S0002-9610(05)80729-9. [DOI] [PubMed] [Google Scholar]
  • 21.Shaha A. Selective surgical management of well-differentiated thyroid cancer. Ann N Y Acad Sci. 2008;1138:58–64. doi: 10.1196/annals.1414.010. [DOI] [PubMed] [Google Scholar]
  • 22.Grillo H.C., Suen H.C., Mathisen D.J., Wain J.C. Resectional management of thyroid carcinoma invading the airway. Ann Thorac Surg. 1992;54(1):3–9. doi: 10.1016/0003-4975(92)91131-R. [DOI] [PubMed] [Google Scholar]
  • 23.Clayman G.L., Shellenberger T.D., Ginsberg L.E., et al. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head Neck. 2009;31(9):1152–1163. doi: 10.1002/hed.21079. [DOI] [PubMed] [Google Scholar]
  • 24.Mazzaferri E.L., Doherty G.M., Steward D.L. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–689. doi: 10.1089/thy.2009.1578. [DOI] [PubMed] [Google Scholar]
  • 25.Sugitani I., Fujimoto Y., Yamada K., Yamamoto N. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg. 2008;32(11):2494–2502. doi: 10.1007/s00268-008-9711-9. [DOI] [PubMed] [Google Scholar]
  • 26.Chisholm E.J., Kulinskaya E., Tolley N.S. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135–1139. doi: 10.1002/lary.20236. [DOI] [PubMed] [Google Scholar]
  • 27.Grubbs E.G., Evans D.B. Role of lymph node dissection in primary surgery for thyroid cancer. J Natl Compr Canc Netw. 2007;5(6):623–630. doi: 10.6004/jnccn.2007.0053. [DOI] [PubMed] [Google Scholar]
  • 28.Patel K.N., Shaha A.R. Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2005;13(2):112–116. doi: 10.1097/01.moo.0000156161.82671.43. [DOI] [PubMed] [Google Scholar]
  • 29.Tuttle R.M., Grewal R.K., Larson S.M. Radioactive iodine therapy in poorly differentiated thyroid cancer. Nat Clin Pract Oncol. 2007;4(11):665–668. doi: 10.1038/ncponc0979. [DOI] [PubMed] [Google Scholar]
  • 30.Tuttle R.M., Leboeuf R., Shaha A.R. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol. 2008;97(8):712–716. doi: 10.1002/jso.21010. [DOI] [PubMed] [Google Scholar]
  • 31.Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26(8):879–885. doi: 10.1007/s00268-002-6612-1. [DOI] [PubMed] [Google Scholar]
  • 32.Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428. doi: 10.1016/0002-9343(94)90321-2. [DOI] [PubMed] [Google Scholar]
  • 33.Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc. 1995;106:151–168. [PMC free article] [PubMed] [Google Scholar]
  • 34.Tuttle R.M., Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw. 2007;5(6):641–646. doi: 10.6004/jnccn.2007.0055. [DOI] [PubMed] [Google Scholar]

Articles from The Indian Journal of Surgery are provided here courtesy of Springer

RESOURCES